Targeting Bruton Tyrosine Kinase: A novel strategy in the treatment of B-cell lymphomas
References
- Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226–233.10.1038/361226a08380905
- Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993;72:279–290.10.1016/0092-8674(93)90667-F
- Thomas DJ, Sideras P, Smith CI, Vorechovsky I, Chapman V, Paul WE. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science. 1993;261:355–8.833290010.1126/science.8332900
- Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, Cohen L et al. Mutation of unique region of Bruton’s tyrosine kinase in immunodeficient XID mice. Science. 1993;261:358–61.833290110.1126/science.8332901
- Khan WN. Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase. Immunol Res. 2001;23(2-3):147-56.1144438010.1385/IR:23:2-3:147
- Fruman DA, Satterthwaite AB, Witte ON. Xid-like phenotypes: a B cell signalosome takes shape. Immunity. 2000;13(1):1-3.10.1016/S1074-7613(00)00002-9
- Smith CI, Baskin B, Humire-Greiff P, Zhou JN, Olsson PG, Maniar HS et al. Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol. 1994;152:557–565.
- Mohamed AJ, Yu L, Bäckesjö CM, Vargas L, Faryal R, Aints A et al. Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228(1):58-73.10.1111/j.1600-065X.2008.00741.x
- Mohamed AJ, Nore BF, Christensson B, Smith CI. Signalling of Bruton’s tyrosine kinase, Btk. Scand J Immunol. 1999;49(2):113-8.10.1046/j.1365-3083.1999.00504.x10075013
- Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol. 2002;2(12):945-56.10.1038/nri95512461567
- Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science. 2002;296(5573):1641-2.1204017710.1126/science.1071546
- Kurosaki T, Takata M, Yamanashi Y, Inazu T, Taniguchi T, Yamamoto T et al. Syk activation by the Src-family tyrosine kinase in the B cell receptor signaling. J Exp Med. 1994;179(5):1725-9.10.1084/jem.179.5.1725
- Kurosaki T, Johnson SA, Pao L, Sada K, Yamamura H, Cambier JC. Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling. J Exp Med. 1995;182(6):1815-23.10.1084/jem.182.6.1815
- Varnai P, Rother KI, Balla T. Phosphatidylinositol 3-kinase-dependentmembrane association of the Bruton’s tyrosine kinase pleckstrin homology domain visualized in single living cells. J Biol Chem 1999;274(16):10983–10989.10.1074/jbc.274.16.1098310196179
- Yang W, Desiderio S. BAP-135, a target for Bruton’s tyrosine kinase in response to B cell receptor engagement. Proc Natl Acad Sci U S A. 1997;94(2):604–609.10.1073/pnas.94.2.604
- Park H, Wahl MI, Afar DE, Turck CW, Rawlings DJ, Tam C et al. Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity. 1996;4(5):515–525.10.1016/S1074-7613(00)80417-38630736
- Rodriguez R, Matsuda M, Perisic O, Bravo J, Paul A, Jones NP et al. Tyrosine residues in phospholipase Cgamma2 essential for the enzyme function in B-cell signaling. J BiolChem. 2001;276(51):47982– 47992.
- Humphries LA, Dangelmaier C, Sommer K, Kipp K, Kato RM, Griffith N et al. Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linker. J Biol Chem. 2004;279(36):37651-61.10.1074/jbc.M31198520015184383
- Liu JL, Chiles TC, Sen RJ, Rothstein TL. Inducible nuclear expression of NF-kappa B in primary B cells stimulated through the surface Ig receptor. J Immunol. 1991;146(5):1685-91.1993849
- Saito K, Tolias KF, Saci A, Koon HB, Humphries LA, Scharenberg A et al. BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activity. Immunity. 2003;19(5):669-78.1461485410.1016/S1074-7613(03)00297-8
- de Gorter DJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW et al. Bruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity. 2007;26:93-104.10.1016/j.immuni.2006.11.01217239630
- Ortolano S, Hwang IY, Han SB, Kehrl JH. Roles for phosphoinositide 3-kinases, Bruton’s tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. Eur J Immunol. 2006;36:1285-1295.10.1002/eji.200535799
- Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med. 2008;264(6):549-62.1901717910.1111/j.1365-2796.2008.02030.x
- Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011;2011:96-103.22160019
- Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen SL et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515– 25.10.1172/JCI30099788964
- Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol. 2003;21:841-94.10.1146/annurev.immunol.21.120601.141018
- Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, Scielzo C et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood. 2008;111(3):1524-1533.17959859
- Tobin G, Thunberg U, Johnson A, Eriksson I, Soderberg O, Karlsson K et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood. 2003;101:4952–7.10.1182/blood-2002-11-348512586612
- Widhopf GF 2nd, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood. 2004;104:2499–504.1521782810.1182/blood-2004-03-0818
- Messmer BT, Albesiano E, Efremov DG, Ghiotto F, Allen SL, Kolitz J et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004;200:519–25.1531407710.1084/jem.20040544
- Tobin G, Thunberg U, Karlsson K, Murray F, Laurell A, Willander K et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood. 2004;104:2879–85.10.1182/blood-2004-01-013215217826
- Potter KN, Orchard J, Critchley E, Mockridge CI, Jose A, Stevenson FK. Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoire. Blood. 2003;101:3082–4.10.1182/blood-2002-08-243212480699
- Widhopf GF 2nd, Kipps TJ. Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. J Immunol. 2001;166: 95–102.10.4049/jimmunol.166.1.9511123281
- Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood. 2004;103(12):4389-95.1496289710.1182/blood-2003-12-4312
- Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-15.10.1056/NEJMra04172015728813
- Darzentas N, Hadzidimitriou A, Murray F, Hatzi K, Josefsson P, Laoutaris N et al. A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence. Leukemia. 2010;24(1):125-132.10.1038/leu.2009.18619759557
- Mockridge CI, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood. 2007;109(10):4424-31.1725535510.1182/blood-2006-11-056648
- Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118(16):4313-20.2181683310.1182/blood-2011-06-338855
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein Harald et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon 2008;2:180-2.
- Hadzidimitriou A, Agathangelidis A, Darzentas N, Murray F, Delfau-Larue MH, Pedersen LB et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood. 2011;118(11):3088-95.10.1182/blood-2011-03-343434
- Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117(1):26-38.2094041510.1182/blood-2010-04-189977
- Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88-92.10.1038/nature0863820054396
- Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88-94.10.1200/JCO.2012.42.790623045577
- Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. 2013;122(7):1222-32.10.1182/blood-2012-12-47511123836557
- Fernandez-Vega I, Quiros LM, Santos-Juanes J, Pane-Foix M, Marafioti T. Bruton’s tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma. Virchows Arch. 2015;466:229-235.10.1007/s00428-014-1698-z
- Hamadani M, Balasubramanian S, Hari PN. Ibrutinib in Refractory Classic Hodgkin’s Lymphoma. N Engl J Med. 2015;373(14):1381-2.2642274310.1056/NEJMc1505857
- Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013;6(1):88.10.1186/1756-8722-6-8824261963
- ten Hacken E, Burger JA. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor. Clin Cancer Res. 2014;20(3):548-56.10.1158/1078-0432.CCR-13-022624323900
- Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075–13080.2061596510.1073/pnas.1004594107
- Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287-96.10.1182/blood-2011-01-32848421422473
- Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182-9.10.1182/blood-2011-10-38641722180443
- Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.10.1056/NEJMoa121563723782158
- O’Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48-58.10.1016/S1470-2045(13)70513-824332241
- Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM et al; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-23.2488163110.1056/NEJMoa1400376
- Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497-506.2570043210.1182/blood-2014-10-606038
- Burger JA, Tedeschi A, Barr PM, Tadeusz R, Owen C, Ghia P et al. RESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015;373(25):2425-37.2663914910.1056/NEJMoa1509388
- Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-16.10.1056/NEJMoa130622023782157
- Wang M, Rule S, Martin P, Goy A, Auer R, Kahl B et al. (2014b) Single-agent ibrutinib demonstrates safety and durability of response at 2 years follow-up in patients with relapsed or refractory mantle cell lymphoma: updated results of an international, multicenter, open-label phase 2 study. Blood. (ASH Annual Meeting Abstracts) abstract 4453.
- Stephens DM, Spurgeon SE. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Ther Adv Hematol. 2015;6(5):242-52.2642533710.1177/2040620715592569
- Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372(15):1430-40.10.1056/NEJMoa150154825853747
- Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922-6.10.1038/nm.388426193343
- Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9:21.10.1186/s13045-016-0250-926957112
Language: English
Page range: 7 - 14
Submitted on: Sep 8, 2016
Accepted on: Aug 24, 2017
Published on: Jun 30, 2017
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Related subjects:
© 2017 R. Sklavenitis-Pistofidis, T. Koletsa, A. Lazaridou, A. Goulas, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.